Pasithea Therapeutics Corp (KTTA)
NASDAQ:KTTA
KTTA Stock Chart & Stats
$0.77
-$0.19(-6.35%)
At close: 4:00 PM EST
$0.77
-$0.19(-6.35%)
Day’s Range― - ―
52-Week Range$0.28 - $3.79
Previous CloseN/A
Volume25.24K
Average Volume (3M)98.68K
Market Cap
$19.20M
Enterprise Value-$55.15B
Total Cash (Recent Filing)$55.16B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta4.11
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding24,939,947
10 Day Avg. Volume100,274
30 Day Avg. Volume98,683
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-2.87K
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda2.74K
Forecast
1Y Price Target
$3.00Price Target Upside289.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet And FinancingA strengthened cash position from recent financing provides resources and flexibility to advance multiple clinical programs and reduce funding risk for ongoing development.
Clinical Data ReadoutsPlanned clinical data releases from early trials could materially affect valuation if results demonstrate clear safety and efficacy for PAS-004 in neurofibromatosis and cancer cohorts.
Drug Design And DifferentiationPAS-004's macrocyclic structure and next-generation MEK inhibitor design could improve target binding, selectivity, and oral availability compared with earlier MEK therapies, supporting best-in-class potential.
Bears Say
Execution RiskBroad trial requirements and multiple program milestones increase execution risk for the development plan, heightening the chance of missed milestones and investor disappointment.
Pediatric Study ObligationsRequirement to expand development into pediatric studies adds complexity and enrollment challenges that could delay approval and increase development costs.
Regulatory RequirementsMarketing approval depends on completion of registrational clinical trials, creating regulatory risk if pivotal studies do not meet required endpoints.
Pasithea Therapeutics Corp News
KTTA FAQ
What was Pasithea Therapeutics Corp’s price range in the past 12 months?
Pasithea Therapeutics Corp lowest stock price was $0.28 and its highest was $3.79 in the past 12 months.
What is Pasithea Therapeutics Corp’s market cap?
Pasithea Therapeutics Corp’s market cap is $19.20M.
When is Pasithea Therapeutics Corp’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pasithea Therapeutics Corp’s earnings last quarter?
Currently, no data Available
Is Pasithea Therapeutics Corp overvalued?
According to Wall Street analysts Pasithea Therapeutics Corp’s price is currently Undervalued.
Does Pasithea Therapeutics Corp pay dividends?
Pasithea Therapeutics Corp does not currently pay dividends.
What is Pasithea Therapeutics Corp’s EPS estimate?
Pasithea Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pasithea Therapeutics Corp have?
Pasithea Therapeutics Corp has 24,939,947 shares outstanding.
What happened to Pasithea Therapeutics Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pasithea Therapeutics Corp?
Currently, no hedge funds are holding shares in KTTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pasithea Therapeutics Corp
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
KTTA Stock 12 Month Forecast
Average Price Target
$3.00
▲(289.61% Upside)
Technical Analysis
Ownership Overview
1.61% Insiders
0.33% Mutual Funds
36.70% Other Institutional Investors
59.66% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---